Xeris Pharmaceuticals | XERS - Debt


Xeris Pharmaceuticals reported $257.65M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Celltrion KRW 161.31B 9.78B Dec/2025
Cspc Pharmaceutical CNY 495M 12.33M Jun/2025
Deva Holding AS TRY 5.3B 871.93M Sep/2023
Dianthus Therapeutics USD 1.28M 45K Sep/2025
Divis Laboratories Ltd INR 40M 40M Mar/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Kangmei Pharma CNY 173.71M 42.08M Mar/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
Laboratorios Farma EUR 129.3M 14.89M Jun/2025
Malin Corporation EUR 100K 0 Dec/2023
Medical Developments International AUD 1.99M 152K Jun/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neuren Pharmaceuticals AUD 0 0 Dec/2024
Ovoca Bio EUR 0 0 Jun/2021
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.64B 4.5M Dec/2025
Pharma Mar EUR 47.54M 1.88M Mar/2026
Qiagen NV USD 1.81B 314.82M Dec/2025
Sartorius EUR 4.28B 372.9M Dec/2025
Sino Biopharmaceutical CNY 9.71B 33.98M Dec/2024
Supernus Pharmaceuticals USD 40.98M 1.23M Dec/2025
Tilray USD 640.95M 35.17M Jun/2022
Zz Pientze Pharmaceu CNY 1.07B 2.82M Mar/2026